vs
RGC RESOURCES INC（RGCO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
RGC RESOURCES INC的季度营收约是REGENXBIO Inc.的1.0倍（$30.6M vs $30.3M），RGC RESOURCES INC净利率更高（16.0% vs -221.3%，领先237.3%），REGENXBIO Inc.同比增速更快（43.0% vs 13.9%），RGC RESOURCES INC自由现金流更多（$-4.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.4%）
伊鲁卡资源是一家澳大利亚资源企业，专注于砂矿勘探、项目开发、运营与营销。该公司在1998年7月由西澳砂矿公司与RGC有限公司的钛矿物业务合并而成，1999年正式定名为伊鲁卡资源有限公司。它是全球主要的锆石、二氧化钛衍生金红石及合成金红石生产商，在澳大利亚拥有运营业务，也曾在美国等地区开展业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
RGCO vs RGNX — 直观对比
营收规模更大
RGCO
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出29.1%
13.9%
净利率更高
RGCO
高出237.3%
-221.3%
自由现金流更多
RGCO
多$48.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.6M | $30.3M |
| 净利润 | $4.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 21.4% | -190.0% |
| 净利率 | 16.0% | -221.3% |
| 营收同比 | 13.9% | 43.0% |
| 净利润同比 | -7.3% | -31.2% |
| 每股收益（稀释后） | $0.47 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGCORGNX
| Q4 25 | $30.6M | $30.3M | ||
| Q3 25 | $14.0M | $29.7M | ||
| Q2 25 | $16.6M | $21.4M | ||
| Q1 25 | $36.5M | $89.0M | ||
| Q4 24 | $26.8M | $21.2M | ||
| Q3 24 | $12.8M | $24.2M | ||
| Q2 24 | $13.6M | $22.3M | ||
| Q1 24 | $30.8M | $15.6M |
净利润RGCORGNX
| Q4 25 | $4.9M | $-67.1M | ||
| Q3 25 | $-204.3K | $-61.9M | ||
| Q2 25 | $538.4K | $-70.9M | ||
| Q1 25 | $7.7M | $6.1M | ||
| Q4 24 | $5.3M | $-51.2M | ||
| Q3 24 | $140.8K | $-59.6M | ||
| Q2 24 | $156.7K | $-53.0M | ||
| Q1 24 | $6.4M | $-63.3M |
毛利率RGCORGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率RGCORGNX
| Q4 25 | 21.4% | -190.0% | ||
| Q3 25 | -3.4% | -176.3% | ||
| Q2 25 | 7.2% | -296.3% | ||
| Q1 25 | 28.5% | 13.6% | ||
| Q4 24 | 27.3% | -242.1% | ||
| Q3 24 | 1.9% | -256.6% | ||
| Q2 24 | 11.5% | -251.3% | ||
| Q1 24 | 28.0% | -408.8% |
净利率RGCORGNX
| Q4 25 | 16.0% | -221.3% | ||
| Q3 25 | -1.5% | -208.3% | ||
| Q2 25 | 3.2% | -331.8% | ||
| Q1 25 | 21.1% | 6.8% | ||
| Q4 24 | 19.6% | -241.3% | ||
| Q3 24 | 1.1% | -246.3% | ||
| Q2 24 | 1.2% | -237.7% | ||
| Q1 24 | 20.9% | -405.4% |
每股收益（稀释后）RGCORGNX
| Q4 25 | $0.47 | $-1.30 | ||
| Q3 25 | $-0.01 | $-1.20 | ||
| Q2 25 | $0.05 | $-1.38 | ||
| Q1 25 | $0.74 | $0.12 | ||
| Q4 24 | $0.51 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $0.63 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $116.4M | $102.7M |
| 总资产 | $341.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RGCORGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益RGCORGNX
| Q4 25 | $116.4M | $102.7M | ||
| Q3 25 | $113.6M | $161.5M | ||
| Q2 25 | $116.3M | $213.7M | ||
| Q1 25 | $117.8M | $274.2M | ||
| Q4 24 | $111.8M | $259.7M | ||
| Q3 24 | $108.1M | $301.4M | ||
| Q2 24 | $108.8M | $348.3M | ||
| Q1 24 | $110.5M | $390.7M |
总资产RGCORGNX
| Q4 25 | $341.0M | $453.0M | ||
| Q3 25 | $329.8M | $525.2M | ||
| Q2 25 | $324.8M | $581.0M | ||
| Q1 25 | $326.4M | $490.9M | ||
| Q4 24 | $335.2M | $466.0M | ||
| Q3 24 | $320.7M | $519.1M | ||
| Q2 24 | $314.2M | $569.4M | ||
| Q1 24 | $313.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-4.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | -14.9% | -174.0% |
| 资本支出强度资本支出/营收 | 18.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流RGCORGNX
| Q4 25 | $1.1M | $-52.3M | ||
| Q3 25 | $675.1K | $-56.0M | ||
| Q2 25 | $6.4M | $-49.3M | ||
| Q1 25 | $21.0M | $33.6M | ||
| Q4 24 | $827.2K | $-31.6M | ||
| Q3 24 | $377.4K | $-40.5M | ||
| Q2 24 | $5.9M | $-45.5M | ||
| Q1 24 | $11.8M | $-55.5M |
自由现金流RGCORGNX
| Q4 25 | $-4.6M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $1.4M | $-49.7M | ||
| Q1 25 | $16.1M | $32.6M | ||
| Q4 24 | $-4.9M | $-32.7M | ||
| Q3 24 | $-5.1M | $-40.9M | ||
| Q2 24 | $564.7K | $-46.0M | ||
| Q1 24 | $5.8M | $-56.0M |
自由现金流率RGCORGNX
| Q4 25 | -14.9% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | 8.4% | -232.8% | ||
| Q1 25 | 44.1% | 36.6% | ||
| Q4 24 | -18.3% | -154.2% | ||
| Q3 24 | -40.2% | -168.9% | ||
| Q2 24 | 4.2% | -206.2% | ||
| Q1 24 | 18.8% | -358.5% |
资本支出强度RGCORGNX
| Q4 25 | 18.5% | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 30.4% | 1.8% | ||
| Q1 25 | 13.6% | 1.2% | ||
| Q4 24 | 21.4% | 5.1% | ||
| Q3 24 | 43.2% | 1.3% | ||
| Q2 24 | 39.0% | 2.1% | ||
| Q1 24 | 19.4% | 3.6% |
现金转化率RGCORGNX
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 11.96× | — | ||
| Q1 25 | 2.74× | 5.53× | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | 2.68× | — | ||
| Q2 24 | 37.36× | — | ||
| Q1 24 | 1.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGCO
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
